MedTrace Logo

Fluid Biopsy for the Diagnosis of Lung Cancer

NCT04162678 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2025-09-05

No results posted yet for this study

Summary

This trial collects and studies blood samples via fluid biopsy for the diagnosis of lung cancer. Studying blood samples in the laboratory may help doctors develop a blood test for lung cancer in the future and provide a better way to screen patients for lung cancer.

Conditions

  • Lung Carcinoma

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood via HD-SCA fluid biopsy

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Liquid Biopsy

Undergo collection of blood via HD-SCA fluid biopsy

OTHER

Medical Chart Review

Review of medical chart

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • University of Southern California

    lead OTHER

Principal Investigators

  • Jorge J Nieva, MD · University of Southern California

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-13
Primary Completion
2024-12-05
Completion
2024-12-09

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162678 on ClinicalTrials.gov